Recent developments highlight Capricor's ongoing clinical and regulatory activities for Deramiocel, including Q2 2026 earnings call insights and FDA approval pathway progress.

• Capricor reported Q2 2026 earnings call highlights discussing clinical progress and regulatory status of Deramiocel [N1].
• The company has maintained relative strength in the market amid ongoing FDA review and clinical data presentations [N2].
• Capricor continues to engage with the FDA regarding approval pathways for its Duchenne cell therapy [N3].
• Q1 2026 earnings transcripts and call highlights provided updates on clinical trial data and company strategy [N4][N5].
• The company emphasized positive functional gains in Duchenne muscular dystrophy from HOPE-3 trial data [N7].
• Q4 2025 earnings call transcript reviewed prior clinical progress and financial status [N8].

Capricor has advanced Deramiocel through multiple clinical trials demonstrating statistically significant efficacy on functional and cardiac endpoints in DMD patients, including non-ambulatory individuals. The ongoing FDA review with a PDUFA date in August 2026 represents a critical regulatory milestone. The company’s exosome platform and vaccine candidate diversify its pipeline. Strong liquidity supports continued development and commercialization efforts. Strategic partnerships, including exclusive distribution agreements, may facilitate market access and expansion.

Capricor has no approved products and has reported net losses, reflecting the risks inherent in clinical development and regulatory approval processes. The FDA previously issued a Complete Response Letter requesting additional data, indicating regulatory challenges. The company’s reliance on external funding and partnerships introduces execution risks. Market adoption and reimbursement for novel cell therapies in rare diseases remain uncertain. The competitive landscape includes other therapeutic approaches targeting DMD, and failure to achieve regulatory approval or commercial success would materially impact the company.

Capricor's moat is based on its proprietary cell therapy technology using cardiosphere-derived cells and its exosome platform, supported by extensive clinical data and collaborations with leading research institutions. The company's focus on Duchenne muscular dystrophy addresses a rare disease with high unmet medical need and limited treatment options, particularly for cardiac complications. The regulatory progress of Deramiocel and the company's manufacturing and commercialization preparations contribute to its competitive positioning. However, as a pre-commercial biotech with no approved products, the moat is contingent on successful regulatory approval and market adoption.

• Regulatory Approval Risk: Deramiocel's approval depends on FDA review outcomes; prior Complete Response Letter indicates regulatory challenges and need for additional data.
• Clinical Development Risk: Clinical trial results, while positive, may not fully predict long-term safety and efficacy or support broad label indications.
• Financial Risk: The company has no product revenue and reports net losses, relying on external funding and partnerships to sustain operations.
• Commercialization Risk: Successful market launch depends on manufacturing scale-up, payer acceptance, and competitive positioning in a rare disease market.
• Competitive Risk: Other therapies targeting DMD, including gene therapies and mutation-specific treatments, may limit market opportunity for Deramiocel.

• Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD).
• The lead product candidate is Deramiocel, a cell therapy composed of cardiosphere-derived cells (CDCs) targeting cardiac and skeletal muscle complications in DMD.
• Deramiocel's mechanism involves immunomodulatory, anti-inflammatory, pro-angiogenic, and anti-fibrotic activities mediated partly by exosomes containing bioactive molecules.
• DMD is a rare genetic disorder causing progressive muscle degeneration and cardiomyopathy, with no current cure and significant unmet medical need.
• Deramiocel's Biologics License Application (BLA) is under FDA review with a PDUFA target action date of August 22, 2026.
• The company completed a Phase 3 HOPE-3 trial showing statistically significant slowing of disease progression on primary and key secondary endpoints, including upper limb function and left ventricular ejection fraction.
• Additional analyses from HOPE-3 showed reduction in myocardial fibrosis and improvements in cardiac function measures.
• Deramiocel has also been studied in Phase 2 (HOPE-2) and earlier trials, demonstrating safety and efficacy signals.
• Capricor has no products approved for commercial sale and no reported revenue as of fiscal year 2025.
• The company plans to commercialize Deramiocel in the US and seek partners for international markets, with Nippon Shinyaku as exclusive US and Japan distributor for DMD.
• Capricor is developing an exosome-based vaccine candidate for SARS-CoV-2 in collaboration with NIH, currently in Phase 1 clinical study.
• The company has received approximately $600 million in funding from equity financings, collaborations, grants, and government programs.
• As of June 30, 2026, Capricor had $20.9 million in cash and equivalents, $242.1 million in current assets, $32.9 million in current liabilities, a current ratio of 7.35, and a cash ratio of 3.03, indicating strong liquidity.
• Net loss for Q2 2026 was $40.7 million with basic and diluted EPS of -$0.7 per share.
• Recent news includes Q2 earnings call highlights, FDA approval pathway discussions, and clinical data presentations supporting Deramiocel's development and regulatory review.